$4.2M Options Underwriting Agreement Executed
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Alterity Therapeutics Ltd. has entered into an underwriting agreement for listed options, which is expected to raise significant funds for clinical development and working capital. The agreement involves underwriting up to a total of unexercised options, with a potential minimum raise before costs. The filing outlines termination events that could affect the underwriting agreement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Appendix 4E and 2026 Annual Report
- Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
- Granted New U.S. Composition of Matter Patent for ATH434
- Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Later from Alterity Therapeutics
- Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
- Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics